Search results
Results from the WOW.Com Content Network
Johnson & Johnson must pay $8 billion in punitive damages to a man who previously won $680,000 over his claims that it failed to warn that young men using its antipsychotic drug Risperdal could ...
“All the big pharmas” have lawsuits, the analyst concluded, sipping an espresso. “It’s just not a big deal.” Indeed, with before-tax profits of $20.6 billion for 2014, putting aside $500 million or even $1 billion a year over 15 years to cover payouts for boys with 46DD breasts and other claims that might come along doesn’t put much ...
Personal injury lawyers were piling on, too, using websites, Google search advertising, social media and TV ads to gather clients who could claim they had been injured by Risperdal—and in some cases the competitor drugs sold by Eli Lilly or AstraZeneca. (Their Google ads are still there; search “Risperdal lawsuits.”
The settlement amount includes both the civil (False Claims Act) settlement and criminal fine. Glaxo's $3 billion settlement included the largest civil False Claims Act settlement on record, [1] and Pfizer’s $2.3 billion ($3.5 billion in 2022) settlement including a record-breaking $1.3 billion criminal fine. [2]
The following is a list of the 21 largest civil settlements, reached between the United States Department of Justice and pharmaceutical companies from 2001 to 2017, ordered by the size of the total civil settlement. Some of these matters also resolved criminal fines and penalties, listed in parentheses, but these amounts are not considered when ...
On the trading day before the settlement was announced, Johnson & Johnson stock closed at $93.37. A week after the announcement, it closed at $94.29. A year later, as thousands of Risperdal personal injury suits were pending, it would close at $108.62.
The following are settlements reached with US authorities against pharmaceutical companies to resolve allegations of "off-label" promotion of drugs. Under the Federal Food, Drug, and Cosmetic Act, it is illegal for pharmaceutical companies to promote their products for uses not approved by the Food and Drug Administration (FDA), and corporations that market drugs for off-label indications may ...
Johnson & Johnson (NYS: JNJ) has come to terms with the Justice Department on one Risperdal marketing charge. It's a single misdemeanor, stemming from a long-running investigation of allegations ...